XORTX Therapeutics Appoints Industry Leader to Board
Company Announcements

XORTX Therapeutics Appoints Industry Leader to Board

Xortx Therapeutics (TSE:XRTX) has released an update.

XORTX Therapeutics Inc. has announced the appointment of biotech industry leader Abigail Jenkins to its Board of Directors, bringing over two decades of experience in advancing therapies from research to commercialization. Her expertise is expected to be particularly valuable as XORTX transitions from a Phase 3 clinical company towards commercializing its drug candidates. Jenkins holds impressive credentials, including a Master of Science from Johns Hopkins University, and has been recognized as a transformative leader in the industry.

For further insights into TSE:XRTX stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskXORTX Outlines Executive Compensation Strategy
TipRanks Auto-Generated NewsdeskXORTX Therapeutics Plans Major Warrant Repricing
TipRanks Auto-Generated NewsdeskXORTX Therapeutics Showcases Progress at BIO 2024
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Optimize your mobile reading experience. Download the TipRanks App today!